Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06979453 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 study of Plaque Psoriasis, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
366
Enrollment target
20
Study locations

NCT06979453 is a Phase 3 study of Plaque Psoriasis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 366 participants, below the 408-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06979453, a Phase 3 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
366 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Conditions Studied

Plaque Psoriasis

Interventions

  • OTHER Placebo
  • DRUG Deucravacitinib

Study Locations (20)

California

  • Local Institution - 0025 - Fountain Valley
  • Center For Dermatology Clinical Research, Inc. - Fremont
  • Dermatology Research Associates - Los Angeles
  • Northridge Clinical Trials - Northridge
  • Local Institution - 0077 - Sacramento
  • Golden State Dermatology - Walnut Creek - Ygnacio Valley Road - Walnut Creek

Florida

  • Local Institution - 0021 - Clearwater
  • Life Clinical Trials - Margate
  • Skin Research of South Florida - Miami
  • Wellness Clinical Research - Miami Lakes
  • Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research - Tampa

Alabama

  • Local Institution - 0261 - Birmingham
  • Local Institution - 0041 - Birmingham

Georgia

  • Dermatology Affiliates Research Institute - Atlanta
  • Advanced Medical Research, PC. - Sandy Springs

Arizona

  • Local Institution - 0053 - Phoenix

Colorado

  • Paradigm Clinical Research, LLC - Wheat Ridge

Indiana

  • Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Kentucky

  • Local Institution - 0262 - Murray

Trial Details

FieldValue
Enrollment Target 366 participants
Start Date 2025-12-03
Est. Completion 2034-08-12
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06979453

The ClinicalTrials.gov registry entry for NCT06979453 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (10% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06979453 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06979453 about?

NCT06979453 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

What is the current status of trial NCT06979453?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2025-12-03. Estimated completion is 2034-08-12.

What conditions does trial NCT06979453 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT06979453?

The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).

Who is sponsoring clinical trial NCT06979453?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06979453 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plaque Psoriasis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.